Mexico Infectious Disease Drugs Market Analysis Report 2022 to 2030

Mexico Infectious Disease Drugs Market Analysis

$ 3999

Mexico Infectious Disease Drugs Market valued at $1.78 Bn in 2023, projected to reach $2.43 Bn by 2030 with a 4.52% CAGR. The market is being driven by advancements in healthcare infrastructure, government initiatives, and rising awareness about infectious diseases. The market is dominated by key players like AbbVie Inc., Gilead Sciences, GlaxoSmithKline plc, Merck & Co., F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, Janssen Pharmaceuticals, Novartis AG, Sanofi S.A., Bayer AG, and Astellas Pharma Inc.

ID: IN10MXPH012 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Aneri Parekh

Buy Now

Mexico Infectious Disease Drugs Market Executive Summary

Mexico Infectious Disease Drugs Market valued at $1.78 Bn in 2023, projected to reach $2.43 Bn by 2030 with a 4.52% CAGR.

Infectious disease drugs in Mexico are used to treat, prevent, and control infectious diseases. This includes a broad spectrum of illnesses brought on by pathogens, including bacteria, viruses, fungi, and parasites. Some of these illnesses include hepatitis, TB, lung infections, gastrointestinal infections, and sexually transmitted infections. The market entails assessing these medications' accessibility, effectiveness, availability, and regulatory issues within Mexico's healthcare system.

Rising government initiatives for the development of healthcare infrastructure and the incidence of infectious diseases are driving the market for infectious disease medications in Mexico, which is growing steadily. The market is expected to grow further because of the pharmaceutical industry's increasing emphasis on research and development and the increase of healthcare services' accessibility. To obtain a competitive advantage in this ever-changing market landscape, major businesses are actively involved in strategic partnerships and product innovation.

The estimated value of the global market for medications used to treat infectious diseases in 2023 was $118.75 Bn. This growth is the result of both an increase in diagnoses and government initiatives aimed at educating the public about the prevention and control of infectious diseases. A shifting market environment is indicated by the growing degree of generic competition. Removing financial obstacles and enhancing treatment accessibility are necessary for long-term growth, particularly in developing countries. This will encourage more innovations and breakthroughs in the sector.

AbbVie is a major player in the infectious disease drugs market in Mexico, especially in treating Hepatitis C Virus (HCV) infections. Their broad range of exceptionally effective HCV drugs tackles a significant public health issue in Mexico. Given AbbVie's dedication to innovation and meeting unmet medical needs, the Mexican market may continue to grow.

Mexico infectious disease drugs market

Market Dynamics

Market Growth Drivers:

Awareness and Screening: Government and healthcare organizations enhance awareness of infectious diseases and early detection and treatment, resulting in higher screening rates. This increases infectious disease drug demand.

Government Initiatives: The fight against infectious illnesses is greatly aided by government initiatives. Access to treatment and prevention boosts market growth with support from the government.

Healthcare Infrastructure Improvements: Better access to healthcare facilities, diagnostic equipment, and treatment alternatives stimulates the infectious disease drugs market.

Market Restraints:

Prevalence of Counterfeit Drugs: Patients face serious health concerns from the prevalence of counterfeit drugs, which also erodes public confidence in reputable pharmaceutical companies and the healthcare system.

Economic Factors: For a significant portion of the population, the cost of infectious illness medications may be prohibitive due to economic limitations which could result in poor treatment, impeding the market growth.

Regulatory Obstacles: Bureaucratic procedures and regulatory barriers may make it difficult for new infectious disease medications to be approved on time and enter the market. For developing infectious diseases that require prompt action, regulatory clearance delays may delay patient access to novel medicines.

Healthcare Policies and Regulatory Landscape

The Secretariat of Health in Mexico, also known as Secretaría de Salud, is a government organization responsible for regulating pharmaceuticals. In Mexico, the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) collaborates with the Sanitary Authorization Commission (CAS) to supervise the sanitary registration process for pharmaceuticals. The Center for Integrated Services (Centro Integral de Servicios, CIS) is in charge of requests and technical meetings for the COFEPRIS New Molecule Committee. Accessible healthcare is the primary goal of the Mexican government, which also closely controls drug costs. For pricey, innovative medications, this can be a major obstacle, making it challenging for companies to recoup their original costs.

Competitive Landscape

Key Players:

AbbVie Inc.
Gilead Sciences
GlaxoSmithKline plc
Merck & Co.
F. Hoffman-La Roche Ltd.
Boehringer Ingelheim International GmbH
Janssen Pharmaceuticals
Novartis AG
Sanofi S.A.
Bayer AG
Astellas Pharma Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Drug Market Segmentation

By Disease

HIV
Influenza
Hepatitis
Tuberculosis
Malaria
Other

By Treatment

Antibacterial
Antiviral
Antiparasitic
Other

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.